Results from phase III LUMINESCE study of Enspryng (satralizumab), a treatment for generalized myasthenia gravis. Chugai Pharma
Chugai Pharmaceutical Co., Ltd. announced results from the Phase III LUMINESCE study of Enspryng (generic name: satralizumab (genetical recombination)), created by Chugai, as an investigational treatment for generalized myasthenia gravis (gMG).
Statistically significant data was observed in its primary endpoint, however the results did not reach our expectations on the degree of clinical benefit. Enspryng was well tolerated in gMG, with a safety profile consistent with Enspryng in neuromyelitis optica spectrum disorder (NMOSD) which is the medicine’s first indication. Detailed results will be presented as an oral Emerging Science abstract at the American Academy of Neurology (AAN) 2024 Annual Meeting on 15 April in Denver, Colorado.
The results of this study in gMG do not impact Enspryng in NMOSD, in which the medicine is already approved. Chugai, in collaboration with Roche, is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from the inhibition of interleukin-6 (IL-6) signaling, including autoimmune encephalitis (AIE), myelin oligodendrocyte glycoprotein-associated disorder (MOGAD) and thyroid eye disease (TED).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins